Abstract
The American Heart Association (AHA) 2014 guidelines advocate the use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) for primary prevention of atrial fibrillation (AF) in cases of heart failure or hypertension. The intentions in this study were to evaluate
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
